LACHELLE AHLERT: Open Payments
NPI 1689265993 · WASHINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$630 in 41 payments from 17 companies in 2025. Trend: 2023 $727 · 2024 $681 · 2025 $630
Food & beverage: $630
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $190 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Amgen Inc. | 3 | $54 |
| Lilly USA, LLC | 3 | $54 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Corium, LLC | 2 | $26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
Products named: QULIPTA, REXULTI, UBRELVY, OTEZLA, ZEPBOUND, Auvelity, Azstarys, TRELEGY ELLIPTA.
Industry payments across IN — which companies pay providers there.
